The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by efforts to target CLDN18.2 via naked antibody and CAR-T modalities. The gene discussed is CLDN18; the disease is pancreatic adenocarcinoma.